Why Lexaria Shares Are Rising Today - Lexaria Bioscience (NASDAQ:LEXX)

Lexaria Bioscience Corp LEXX said that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 are complete, assessing a single 300mg dose of DehydraTECH-processed cannabidiol (DehydraTECH-CBD).
The study findings indicated a tendency (p=0.1) during 15 minutes of simulated low levels of oxygen (hypoxia) for reduced pulmonary artery systolic pressure (PASP) with DehydraTECH-CBD treatment versus placebo.
PASP was significantly attenuated by about 5 mmHg or 41% overall (p=0.045) in male participants, suggesting differences in sex in responsiveness to CBD treatment under hypoxic stress conditions.
Related: Read Why Lexaria Bioscience Shares Are Surging During Wednesday Premarket?
These findings complement Lexaria's growing body of evidence demonstrating the ability of DehydraTECH-CBD to reduce blood pressure.
"It's a sad fact that most people with hypertension choose not to treat the disease. Lexaria's DehydraTECH-CBD is evidencing time and again an ability to decrease high blood pressure without any material adverse side effects," said Chris Bunka, CEO, in an emailed statement to Benzinga.
"The market demand for a safe and effective new hypertension drug with few side effects can be measured in the billions of dollars," Bunka added.
These new findings from HYPER-H21-3 will help direct future research into the efficacy of DehydraTECH-CBD use to manage elevations in pulmonary arterial pressure under hypoxic conditions, related hypoxemic pathologies, and pulmonary hypertension.
Lexaria intends to use the data from study HYPER-H21-3 and the findings from its other prior studies to support Lexaria's plans for the FDA Investigational New Drug process.
As in past studies, all study participants tolerated DehydraTECH-CBD well, and no serious adverse side effects were recorded.
Price Action: LEXX shares are up 34.8% at $4.42 during the market session on the last check Thursday.
Editor's Note: The post has been updated to include comments from Lexaria's CEO.

Market News and Data brought to you by Benzinga APIs